An Adverse Drug Reaction to Meropenem Antibiotic: A Safety Alert Reported by Indian Pharmacovigilance Systems

References

1. Central drugs standard control organization. Available from:https://cdsco.gov.in/opencms/opencms/en/Home
2. Ahmad A. Patel I. Sanyal S. Balkrishnan R. Mohanta G.P. A study on drug safety monitoring program in India. Indian J. Pharm. Sci. 2014 76 5 379 386 25425751
   [Google Scholar]
3. Vaishnavi G Sachin H Priyanka Y A review on banned drugs. Asian jPharmResdev 202311 6 31 5 10.22270/ajprd.v11i6.1331
   [Google Scholar]
4. Available fromhttps://www.drugscontrol.org/banned-drugs.php
5. Alert DS Indian Pharmacopoeia Commission Flags ADR Linked to Meropenem. Available from:https://medicaldialogues.in/news/industry/pharma/drug-safety-alert-indian-pharmacopoeia-commission-flags-adr-linked-to-meropenem-130437
   [Google Scholar]
6. Fish D.N. Meropenem in the treatment of complicated skin and soft tissue infections. Ther. Clin. Risk Manag. 2006 2 4 401 415 10.2147/tcrm.2006.2.4.401 18360652
   [Google Scholar]
7. Cottagnoud P. Cellular and molecular aspects of drugs of the future: meropenem. Cell. Mol. Life Sci. 2002 59 11 1928 1933 10.1007/PL00012515 12530523
   [Google Scholar]
8. Linden P. Safety profile of meropenem: An updated review of over 6,000 patients treated with meropenem. Drug Saf. 2007 30 8 657 668 10.2165/00002018‑200730080‑00002 17696578
   [Google Scholar]
9. Mysore V. Ghuloom A. A case of recurrent acute generalized exanthematous pustulosis due to beta-lactam antibiotics: A case report. J. Dermatolog. Treat. 2003 14 1 54 56 10.1080/09546630305544 12745858
   [Google Scholar]
10. El-Gamal A-H.F. Khalel M.H. Fattah Saleh S.A. Najem N. Acute generalized exanthematous pustulosis: An unusual side effect of meropenem. Indian J. Dermatol. 2010 55 2 176 177 10.4103/0019‑5154.62759 20606889
    [Google Scholar]
11. Ghoshal L. Nandi S. Sarkar A. Das S. Acute generalized exanthematous pustulosis due to meropenem: An unusual side effect of a commonly used drug. Indian Dermatol. Online J. 2015 6 6 446 448 10.4103/2229‑5178.169711 26751943
    [Google Scholar]
12. Baker H. Ryan T.J. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br. J. Dermatol. 1968 80 12 771 793 10.1111/j.1365‑2133.1968.tb11947.x 4236712
    [Google Scholar]
13. Chohan S. Chronis J. Asif M. An atypical presentation of acute generalized exanthematous pustulosis induced by use of meropenem: A case report and literature review. Cureus 2024 16 8 e68321 10.7759/cureus.68321 39350823
    [Google Scholar]
14. Sidoroff A. Halevy S. Bavinck J.N.B. Vaillant L. Roujeau J.C. Acute generalized exanthematous pustulosis (AGEP) – A clinical reaction pattern. J. Cutan. Pathol. 2001 28 3 113 119 10.1034/j.1600‑0560.2001.028003113.x 11168761
    [Google Scholar]
15. Use of meropenem drug can cause adverse reactions: Health ministry panel
    [Google Scholar]
16. Paul P. Kamal R. Bhatia R. The hidden dangers of meftal: A drug safety alert for a frequently used NSAID. Curr. Pharm. Des. 2024 30 25 1949 1951 10.2174/0113816128304156240606050525 38910273
    [Google Scholar]